Evolution of Therapy for ANCA-Associated Vasculitis with Kidney Involvement

What is it about?

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) belongs to a group of small-vessel systemic inflammation of various tissues. They often involve the kidneys. Although AAV was once associated with severe end-organ damage and extremely high mortality rates, the use of glucocorticoids and cyclophosphamide led to a paradigm shift in its treatment. Over the last 20 years, significant progress in understanding the origin of AAV has enabled development of targeted therapies, providing a much better prognosis for patients. This review describes the evolution of treatment of AAV, particularly for patients with kidney involvement.

Featured Image